MICRO-CT IMAGING OF AVASTIN-TREATED MICE WITH LS174TT TUMORS

阿瓦斯汀治疗的 LS174TT 肿瘤小鼠的显微 CT 成像

• 批准号: 8363176
• 负责人: Christian Tudorel Badea
• 金额: $ 1.23万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-07-01 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8363176
• 关键词: Animals; Avastin; Blood Vessels; Catheters; Contrast Media; Control Animal; Control Groups; Dose; Funding; Grant; Hour; Image; Isovue; Liposomes; Microscopy; Mus; National Center for Research Resources; Perfusion; Permeability; Principal Investigator; Research; Research Infrastructure; Resources; Source; Tail; United States National Institutes of Health; Veins; cost; tumor; Animals; Avastin; Blood Vessels; Catheters; Contrast Media; Control Animal; Control Groups; Dose; Funding; Grant; Hour; Image; Isovue; Liposomes; Microscopy; Mus; National Center for Research Resources; Perfusion; Permeability; Principal Investigator; Research; Research Infrastructure; Resources; Source; Tail; United States National Institutes of Health; Veins; cost; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Aim: Study the hypothesis of vascular normalization as a result of Avastin treatment. We will use both dynamic micro-CT with a Isovue 370 to visualize perfusion and static micro-CT with a liposomal contrast agent to visualize permeability in tumors. 12 animals with viable tumors will be transfered from Piedmont Research Center to Duke on 1-5-10. 6 mice will be treated with Avastin and 6 mice will be controls. Treatment involves 5mg/kg of Avastin given IP biweekly, and will take place on: Thursdays and Mondays starting on Thursday January 7th. The first imaging day will be Friday January 8th. 4 treatment groups: 1) Control Liposome, 3 animals (CL) 2) Control Perfusion, 3 animals (CP) 3) Treated Liposome, 3 animals ( TL) 4) Treated Perfusion, 3 animals (TP) The groups CL and TL will be injected via tail vein with liposomal contrast ( 0.3 ml/25g mouse) on Mondays and static micro-CT imaging will take place on Mondays (0 hours) and Wednesdays (48hours) every week. The groups CP and TP will be imaged once per week on Fridays using dynamic micro-CT to compare perfusion. For these stusdies we will use a tail vein catheter to deliver Isovue 370 in a dose of 0.5ml/25 g mouse). Animals will be recovered after each imaging session. We expect that untreated mice (CL, CP) will reach the end point when they will need to be sacrificed in about 17 days with Day 0 starting on January 5th. The treated animals (TL, TP) will reach the endpoint in about 36 days. Therefore, imaging the 6 animals in groups (CP,CP) will take place for only 2 weeks. For untreated animals the imaging could last up to 5 weeks.

该副本是利用资源的众多研究子项目之一 由NIH/NCRR资助的中心赠款提供。对该子弹的主要支持 而且，副投影的主要研究员可能是其他来源提供的 包括其他NIH来源。 列出的总费用可能 代表subproject使用的中心基础架构的估计量， NCRR赠款不直接向子弹或副本人员提供的直接资金。 目的：研究由于阿瓦司蛋白治疗而导致血管归一化的假设。我们将使用ISOVUE 370使用动态微CT，以可视化灌注和静态微CT具有脂质体对比剂，以可视化肿瘤中的渗透性。 12只具有活肿瘤的动物将于1-5-10从皮埃蒙特研究中心转移到杜克。 6只小鼠将用avastin治疗，6只小鼠将是对照。治疗涉及5mg/kg的avastin双周，并将在1月7日（星期四）开始：星期四和星期一。 第一个成像日将是1月8日，星期五。 4个治疗组： 1）控制脂质体，3只动物（CL） 2）控制灌注，3只动物（CP） 3）处理过的脂质体，3只动物（TL） 4）经过处理的灌注，3只动物（TP） 这些组Cl和TL将通过尾静脉注射，周一，脂质体对比度（0.3 mL/25g小鼠），静态微型CT成像将在每周（0小时）和每周星期三（48小时）进行。 CP和TP组将在星期五使用动态微型CT进行一次成像，以比较灌注。对于这些疾病，我们将使用尾静脉导管以0.5ml/25 g小鼠的剂量输送ISOVUE 370。每次成像会后将恢复动物。我们预计未经治疗的小鼠（CL，CP）将在1月5日开始，第0天需要在大约17天内牺牲它们，将到达终点。经过处理的动物（TL，TP）将在大约36天内到达终点。因此，将6只动物成像成像（CP，CP）只有2周。对于未经处理的动物，成像可能会持续5周。